Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer
This study aims to evaluate the safety and activity of the Avelumab in combination with Carboplatin-Paclitaxel in advanced or recurrent endometrial cancer
Endometrial Cancer
DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Avelumab
progression free survival, 18 months from beginning of treatment
overall survival, 3 years|number of patients with complete and partial responses, 18 months|worst grade toxicity per patient, according to Common Toxicity Criteria for Adverse Events v. 4.03, evaluated every 3 weeks up to 2 years|changes in patient-reported outcome (PRO) scores of quality of life and endometrial cancer disease and treatment related symptoms from baseline, European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C-30 En-24C QOL questionnaire C-30 En-24, up to 2 years|changes in patient-reported outcome (PRO) scores of symptomatic toxicities during treatment, PRO-CTCAE questionnaire, up to 2 years
This study aims to evaluate the safety and activity of the Avelumab in combination with Carboplatin-Paclitaxel in advanced or recurrent endometrial cancer